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Background: Interstitial lung diseases (ILDs) are often associated with rheumatic
diseases. Their early diagnosis and management are not only difficult, but also crucial,
because they are associated with major morbidity andmortality and can be the first cause
of death in autoimmune rheumatic diseases (ARDs).
Objectives: By using methodologies, such as Nominal Group Technique (NGT)
and Delphi Survey, the aims of this study were (1) to measure consensus between
pulmonologists, radiologists, and rheumatologists experienced in the management of
ARD-ILD; (2) to highlight the importance of amultidisciplinary approach; and (3) to provide
clinicians with a practical tool aimed at improving the prompt recognition and follow-up
of ILD associated with ARDs and of any possible rheumatic conditions underlying ILD.
Results: During the NGT round, the Steering Committee defined 57 statements to be
used in the Delphi survey. A total of 78 experts participated in the Delphi survey, namely 28
pulmonologists, 33 rheumatologists, and 17 radiologists. During this round, consensus
on agreement was reached in 47 statements, while disagreement was not reached in any
statements. A secondary questionnaire was drafted by the Steering Committee to obtain
clearer indications on ILD-ARD “red-flags” and follow-up. Delphi Panelists took part also
in the second-questionnaire survey. Answers from both surveys were used to draft two
checklists of “red flags” sign or symptom suggestive of ILD and ARD, respectively, and
two checklists on identification and monitoring of rheumatoid arthritis (RA) and systemic
sclerosis (SSc) ILD.
Limitations: This study is a consensus work, which cannot produce empiric data, and
is limited to the Italian scenario.
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Conclusions: This work showed a high level of agreement, but also shows some
divergent opinions between different experts. This underlines the importance of a
multidisciplinary approach. Eventually, we believe the drafted checklists can help
clinicians in the diagnosis and follow-up of ILD-ARD.
Keywords: interstitial lung disease, autoimmune rheumatic diseases, multidisciplinary team, nominal group
technique, Delphi panel survey, red flags and referral indications, consensus, ARD-ILD
INTRODUCTION
Interstitial lung diseases (ILDs) encompass a heterogeneous
group of clinical conditions characterized by fibrosis of
and/or inflammation the lungs (1). A common cause of ILD
is represented by rheumatic diseases; in these conditions,
lung involvement is not only common, but can be the
main organ involvement (2, 3). Systemic sclerosis (SSc),
rheumatoid arthritis (RA), antisynthetase syndrome, Sjogren’s
syndrome, mixed connective tissue disease (CTD), idiopathic
inflammatory myopathies, and systemic lupus erythematosus
are often associated with ILD (4). Moreover, a recent
international consensus statement proposed “interstitial
pneumonia with autoimmune features” as a new definition
for ILD underlined by systemic autoimmune condition
and not classifiable as any definite CTD, emphasizing
the relationship between ILD and autoimmune response
(5, 6). In patients with rheumatic diseases, ILD is difficult to
diagnose at an early stage, and can be associated with major
morbidity and mortality, or even be the leading cause of
death (7–13).
Interstitial lung diseases should be managed, from its
diagnosis, by a multidisciplinary team (MDT) composed
of at least one pulmonologist, one radiologist, and one
pathologist (2–4, 14). However, since phenotypic features
of both ILDs and systemic autoimmune disorders often
overlap, the patient’s assessment should not be limited
to clinical, radiological, and pathological evaluation, but
should also include a clinical–immunological evaluation.
The inclusion of an expert rheumatologist to the MDT
can significantly reduce invasive procedures and increase
diagnostic accuracy (1, 3, 4, 15). Nonetheless, in daily
practice, it could be of use having specific and easy-to-use
recommendations to improve the diagnosis and follow-up
even for clinicians without specific experience in ARD-
ILD or when an MDT is not available. This would help
reduce diagnostic timing, which is of outmost importance,
since a prompt recognition of the pathology would result in
better outcomes.
Aims of this work were (1) to measure consensus between
pulmonologists, radiologists, and rheumatologists experienced in
the management of ARD-ILD; (2) to highlight the importance
and raise sensibility on the necessity of a multidisciplinary
approach; and (3) to provide clinicians with a practical tool
aimed at improving the prompt recognition and follow-up of ILD
associated with autoimmune rheumatic diseases (ARDs) and of
any possible rheumatic conditions underlying ILD.
METHODS
The project structure is shown in the flowchart (Figure 1).
Briefly, a Steering Committee reviewed the available literature
and identified six key questions, which were used to generate
some statements through the Nominal Group Technique (NGT)
(16). The statements were used for a round of an adapted
Delphi survey for an expert panel. Answers were used to draft
a first checklist and as inputs to design a second, more specific
questionnaire. Eventually, results from the second questionnaire
were integrated with the result of the Delphi survey by the
Steering Committee to define the check lists of red flags and the
timing of ILD screening and monitoring.
Steering Committee and Delphi Expert
Panel
The members of both the Steering Committee and Delphi Panel
are experts on ARD-associated ILDs.
The Steering Committee included different healthcare
professionals, namely three pneumologists (SH, AP, FV), three
rheumatologists (SB, NDP, MS), one immunologist (LB), and
two radiologists (SP, GR). The Steering Committee sought
the assistance of a non-clinical chair from an independent
scientific consultancy agency (Polistudium srl, Milan, Italy)
in order to provide meeting facilitation, material preparation
and scientific accuracy. The Steering Committee designed and
developed the project, identified the expert panel, generated the
statements, reviewed and discussed survey results, and drafted
the checklists.
The expert panel comprised members of different therapeutic
areas in order to achieve a multidisciplinary overview. Inclusion
criteria were clinical experience in ARD associated-ILDs and
proven activity in MDTs. Candidate experts were proposed,
shared, and approved within the Steering Committee.
Literature Review and Key Questions
The Steering Committee with the help of the non-clinical
chair reviewed the most recent literature on the topic and
drafted six key questions to be used to generate statements
through a NGT round. Domains of the questions comprised
(1) risk factors; (2) pulmonary signs and symptoms; (3)
rheumatological signs and symptoms; (4) monitoring timing
and frequency of pulmonary symptoms in ARD and ARD-ILD
patients; (5) rheumatologists’ and pulmonologists’ sensitivity and
attention to the suspicion of ILD; and (6) how to implement
multidisciplinary management.
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FIGURE 1 | Project flowchart.
Statement Definition
The NGT is a direct and structured technique, based on
experts’ opinion, aimed at managing meetings organized to
make decisions on a specific topic on which there is no strong
evidence (16). The NGT was used to generate the statements
for the Delphi Panel. At first, the six key questions were asked
to the members of the steering committee, who then had the
opportunity to independently develop their own thoughts and
opinions during the “silent generation” process. Their opinions
were presented during an online meeting in September 2020,
chaired by a Professional Facilitator. All the opinions (items)
were collected and shared with the participants; with the help
of the facilitator, items were re-elaborated and similar ones were
merged according to a statistical clustering and participants’
opinion to draft preliminary statements. Before reaching a final
formulation, participants had the opportunity to review and/or
comment all items. The so-drafted 57 statements were ranked
through an online survey (due to COVID-19 pandemic) in
terms of priority and relevance using a 1–5 scale during a
second, remotely performed meeting. All 57 statements were
considered relevant and kept, eventually drafting the complete
list of items.
Adapted Delphi Process
The Delphi Method is a standard method of consensus, used to
evaluate in an interactive and anonymous way, through online
surveys, the level of agreement (consensus quantification) using
a Likert scale (1–5; 1 = total disagreement; 5 = total agreement)
and to resolve differences of opinion (consensus development).
It takes place through several phases or rounds of expression
and evaluation of opinions of a group of appropriately selected
experts (17). Consensus on agreement is reached when at least
75% of voters express a vote equal to 4 or 5, according to the
indications of the Ministry of Health (18).
Between December 2020 and January 2021, panelists
participated to the Delphi online survey and indicated their level
of agreement with the statements generated through the NGT.
Second Questionnaire
A qualitative second online survey aimed at outlining, more
precisely, what the red flags are and the timing of ILD screening
and monitoring was drafted by the Steering Committee after the
first Delphi round. The members of the Delphi Panel participated
in the online survey.
Statistical Analysis
All data were analyzed with descriptive statistics.
RESULTS
NGT and Delphi Survey
During the NGT round, the Steering Committee answered six
key questions and defined 57 statements to be used in the Delphi
survey. The key questions statements are reported in Tables 1, 2.
In total, 85 experts from different therapeutic areas were
invited to join the Delphi Panel (Supplementary Appendix A);
all the members were based in Italy.
A total of 78 total experts participated in the Delphi survey,
composed of 28 pulmonologists, 33 rheumatologists, and 17
radiologists. During this round, consensus on agreement was
reached in 47 statements, as shown in Table 1. Consensus on
disagreement was not reached in any statements. Statements
in which consensus was not reached (n = 10) are shown
in Table 2. Due to the practical aim of this paper (i.e., the
creation of a checklist regarding useful red flags to suspect
ILD in ARD patients and vice versa and regarding screening
and monitoring of ILD in ARD patients) this process was
adapted by doing a single round; the first-round responses were
analyzed by the Steering Committee, who reviewed statements
in which consensus had not been reached, discussed the reasons,
and provided inputs for the creation of the second, more-in-
depth questionnaire.
Second Questionnaire
This first round led to some reflections and conclusions from
the committee: (1) there were clear difficulties for reaching
consensus in some cases (cf. statement 1.5); differences in
views holds despite all members being expert on the topic
and part of MDTs—but this is where, in our opinion, value
of multidisciplinary resides; (2) some answers from the Delphi
survey were conflicting and weren’t suitable with our need
to give clear indications on patient management; (3) some
statements were less relevant for the aim of the paper and
were decided not to be investigated with a second round, while
others were vague and interpretable. A further reason resides
on the practical aim of this paper, which lead us in asking
more specific questions to give clearer indications based on
opinions of the large number of experts of the Delphi Panel.
A detailed questionnaire, with a different structure than the
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TABLE 1 | Statements that reached overall consensus.
Statements that reached consensus Level of agreement (%)
Total Pn Rh Ra
Q1: What are the main risk factors for the development of ILD in ARDs?
1.1—ARDs, in particular, systemic sclerosis, rheumatoid arthritis, and anti-synthetase syndrome, have to be considered
important risk factors for the development of ILD.
98 100 94 100
1.2—In the presence of ARDs, the presence of some autoantibodies (anti-JO1, anti-PL 7, anti-PL12, anti-SSA Ro,
anti-MDA 5, anti-Scl70, anti-PM/Scl, anti-Th/To) increase the risk of developing ILD.
94 90 97 94
1.3—Some gene variants are associated with a greater risk of developing ILD, particularly for some forms, such as usual
interstitial pneumonia.
78 87 67 84
1.4—In the case of a patient suffering from systemic sclerosis, there are specific risk factors for the development of ILD,
such as male gender, a diffuse form of the disease, and the presence of anti-Scl70 antibodies.
87 81 97 78
1.6—In patients with rheumatoid arthritis, the risk of developing ILD increases in males, smoking patients, with an older age
of onset, in proportion to the duration of disease, and the titer of anti-citrulline antibodies.
83 84 88 72
Q2: What are the pulmonary signs, symptoms, and investigations that rheumatologists need to evaluate in
generating a suspicion of ILD in patients with ARD?
2.1—A careful anamnesis about the presence of respiratory symptoms is essential in the ARD work-up to evaluate any
symptoms of ILD.
91 97 85 94
2.2—A careful thoracic physical examination is essential in the work up of systemic autoimmune diseases to assess the
presence of ILD.
87 97 76 94
2.3—The presence of dry cough and exertional dyspnea, not justified by an infectious respiratory or cardiological pathology
in progress, can generate the suspicion of ILD in a patient with ARD.
97 100 94 100
2.4—The presence of a feeling of fatigue or chest tightness or digital hippocratism or chest pain can raise the suspicion of
ILD in a patient with ARD.
84 86 82 83
2.5—Presence of basal velcro crackles on chest auscultation may raise the suspicion of ILD in a patient with ARD. 92 100 88 89
2.6—Chest x-ray is a poorly specific and insensitive tool to check for the presence of ILD in a patient with ARD. 86 76 97 83
2.7—Spirometry coupled with the CO diffusion test is an investigation to be performed to monitor the course of ILD in a
patient with ARD.
97 97 97 100
2.8—The high-resolution CT scan of the chest is the most sensitive and specific radiological method to validate the
presence of ILD in a patient with ARD.
100 100 100 100
2.9—If ILD is suspected, a volumetric rather than axial CT scan should be performed, with multiplanar reconstructions and
eventual scans in prone decubitus.
89 90 82 100
2.10—Blood–gas analysis allows to evaluate the degree of impairment of gas exchange at rest during ILD in a patient with
ARD.
80 79 79 83
2.11−6MWT (Six-Minute Walking Test) allows to evaluate the functional consequences of cardio-pulmonary damage during
ILD in a patient with ARD.
80 90 67 89
2.12—In case of systemic sclerosis and anti-synthetase syndrome, high-resolution CT of the chest is already recommended
at diagnosis.
85 83 88 83
2.13—Within the framing work-up of a diffuse type of systemic sclerosis in early phase or in the presence of predisposing
antibodies, high-resolution chest CT scan must always be considered.
92 93 100 78
Q3: What are the rheumatological signs and symptoms that pulmonologists need to evaluate in generating a
suspicion of ARD in patients with ILD?
3.1—Presence of Raynaud’s phenomenon, digital edema, skin sclerosis, digital ulcers, telangiectasias, alone or in
combination, can generate the suspicion of ARD in a patient with ILD.
91 90 94 88
3.2—Presence of skin manifestations (lower limbs purpura, Gottron’s papules, vasculitis, photosensitivity, palmar erythema)
can lead to suspicion of ARD in a patient with ILD.
87 83 91 88
3.3—Presence of skin cracks on fingers (“mechanic’s hands”) can lead to suspicion of ARD in a patient with ILD. 91 86 94 94
3.4—Presence of Sicca syndrome can raise suspicion of ARD in an ILD patient. 76 86 73 94
3.5—The presence of arthralgia and morning stiffness can generate suspicion of ARD in a patient with ILD. 77 80 76 77
3.7—Positivity to antinuclear antibodies of a significant titer or ≥1/320 may raise suspicion of ARD in a patient with ILD. 85 79 85 94
3.12—In patients with ILD, capillaroscopy should be required at least for patients with Raynaud’s phenomenon and for
those with specific autoantibodies for systemic sclerosis, mixed connective tissue disease and myositis (anticentromere,
anti-Scl70, anti-RNP, specific anti-myositis, anti-synthetase)
100 100 100 100
Q4: What should be the monitoring timing and frequency of pulmonary symptoms in the patient with ARD?
4.1—Pulmonary symptoms in the ARD patient should be assessed at each visit. 92 93 93 100
4.3—Timing and frequency of pulmonary symptoms monitoring in the ARD patient depend on the specific rheumatic
disease.
78 76 82 77
(Continued)
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TABLE 1 | Continued
Statements that reached consensus Level of agreement (%)
Total Pn Rh Ra
4.4—In the event of worsening respiratory symptoms in a patient with ARD, a high-resolution chest CT scan should be
performed.
87 100 76 88
4.5—Respiratory function tests and carbon monoxide alveolar–capillary diffusion test (DLCO) should be performed every 12
months in patients with ARD, in case of systemic sclerosis every 6–12 months.
86 90 82 88
4.6—Pulmonary symptoms of patients with systemic sclerosis should be monitored every 6 months in case of progressive
rheumatic disease.
81 90 72 88
4.7—Respiratory function tests and carbon monoxide alveolar–capillary diffusion test (DlCO) should be performed every 12
months in the presence of clinical (systemic sclerosis) or laboratory (predisposing autoantibodies) risk factors in the absence
of proven ILD.
90 93 88 88
Q4.1: What should be the monitoring timing and frequency of pulmonary symptoms in the patient with
ARD–ILD?
4.1.1—In case of patients with ARD and ILD, it is necessary, depending on the severity, to evaluate pulmonary symptoms
every 3–6 months, carry out spirometry tests every 3–6 months, carry out carbon monoxide alveolar–capillary diffusion tests
(DLCO), perform Six-Minute Walking Test (6MWT), and perform echocardiogram every 6–12 months.
85 90 90 71
4.1.2—Possible appearance or progression of ILD must be evaluated, in relation to the disease, by high-resolution CT scan
of the chest as symptoms vary, in the presence of velcro crackles or worsening of functional tests.
98 97 97 100
Q5: What could be the approaches to increase rheumatologists’ and pulmonologists’ sensitivity and attention
to the suspicion of ILD, in the Italian setting?
5.1—The creation of a network between different centers of reference, which also favors the organization of national
collaborative studies between pulmonologists, radiologists, and rheumatologists, can help to increase rheumatologists’ and
pulmonologists’ sensitivity and attention to suspicion of ILD, in the Italian setting.
96 93 97 100
5.2—Webinar organization, seminars with MDT, and monothematic courses at regional and national level can be useful in
increasing rheumatologists’ and pulmonologists’ sensitivity and attention to the suspicion of ILD, in the Italian setting.
87 90 79 100
5.3—Opportunity increase for meeting and updating with experts, through regional periodic scientific tables with simulation
of MDT on paradigmatic cases or participation in multidisciplinary clinics, can be useful to increase rheumatologists’ and
pulmonologists’ sensitivity and attention to the suspicion of ILD, in the Italian setting.
96 93 97 100
5.4—Sharing literature (e.g., creation of a six-monthly scientific bulletin to be distributed to level 1 centers) can be useful in
increasing rheumatologists’ and pulmonologists’ sensitivity and attention to the suspicion of ILD, in the Italian setting.
77 79 70 88
5.5—The creation of an informatic platform, where level 1 centers can ask more specialized centers’ opinion, can serve to
increase rheumatologists’ and pulmonologists’ sensitivity and attention to the suspicion of ILD, in the Italian setting.
82 90 73 88
Q6: What can be ways to implement multidisciplinary management of ARD patients with suspicion of ILD?
6.1—Creation of shared clinics between rheumatologists and pulmonologists can facilitate multidisciplinary management of
rheumatology patients with suspicion of ILD.
95 93 100 82
6.2—Organization of joint training courses between rheumatologists, pulmonologists, radiologists can be useful for
implementing multidisciplinary management of rheumatological patients with suspicion of ILD.
97 96 97 100
6.3—Creation of a preferential path of access to rheumatologists and pulmonologists for patients with suspected ILD,
secondary to ARD, can favor multidisciplinary management of rheumatological patients with suspicion of ILD.
94 89 94 100
6.4—Sharing of diagnostic classification criteria of both ARD and ILD among the rheumatological and pneumological
community, e.g., with the formulation of statements by scientific societies or the organization of regular meetings for the
discussion of cases, would favor a multidisciplinary management of rheumatologic patients with suspicion of ILD.
95 100 88 100
6.5—In the case of patients with lung disease not classified with certainty by the pulmonologist, a rheumatological
evaluation should also be performed.
82 75 82 94
Pn, pneumologists; Rh, rheumatologists; Ra, radiologists. Values in bold highlight an unmet consensus within a specialty.
Delphi, was thus drafted. This included four sections. In section
A, which was addressed only to rheumatologists, the signs and
symptoms they would report as red flags to pulmonologists to
help suspect ILD in patients with ARD were ranked. Section B
had the same structure but was only addressed to pulmonologists
and which red flags they would report to the rheumatologist.
Section C included questions regarding the tests—and their
timing—to be performed on ARD patients without a diagnosis
of ILD both in the presence and absence of risk factors for
developing ILD. Section D questions were the same as section
C but focused on ARD patients with a diagnosis of ILD and
on risk factors for ILD progression rather than ILD developing.
Questions in section C and D also asked to make the considered
risk factors explicit, and to express any adjunctive comments;
moreover, they did not only refer to a generic ARD patient,
but specifically addressed the following rheumatic diseases:
SSc, antisynthetase syndrome, Sjögren’s syndrome, RA, and
undifferentiated CTD.
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TABLE 2 | Statements without overall consensus.
Statements that reached consensus Level of agreement (%)
Total Pn Rh Ra
Q1: What are the main risk factors for the development of ILD in ARDs?
1.5—The severity of skin involvement in case of systemic sclerosis correlates with an increased risk of ILD. 51 26 79 44
1.7—The risk of developing ILD tends to increase with the age of onset of ARD, such as in the case of rheumatoid arthritis. 73 65 79 78
Q3: What are the rheumatological signs and symptoms that pulmonologists need to evaluate in generating a
suspicion of ARD in patients with ILD?
3.6—Presence of joint deformations can raise the suspicion of ARD in a patient with ILD. 71 76 61 82
3.8—Presence of alteration in phlogosis indexes can generate suspicion of ARD in a patient with ILD. 35 31 30 53
3.9—Morning functional impotence can raise suspicion of ARD in a patient with ILD. 53 55 49 59
3.10—Presence of subcutaneous nodules may raise suspicion of ARD in a patient with ILD. 66 62 58 88
3.11—Presence of a feeling of hyposthenia can generate suspicion of ARD in an ILD patient. 44 41 46 47
Q4: What should be the monitoring timing and frequency of pulmonary symptoms in the patient with ARD?
4.2—Pulmonary symptoms in ARD patients should be monitored every 12 months for stable rheumatic disease or low-risk
patients.
70 66 67 82
4.8—In the case of high-risk patients (i.e., diffuse systemic sclerosis with the presence of anti-scl70 antibodies) pulmonary
symptoms should be evaluated every 3 months while high-resolution chest CT should be performed every 12 months.
72 76 67 77
Q6: What can be ways to implement multidisciplinary management of ARD patients with suspicion of ILD?
6.6—Creation of “smart” digital platforms for each MDT group can facilitate multidisciplinary management of rheumatology
patients with suspicion of ILD.
72 68 64 94
Pn, pneumologists; Rh, rheumatologists; Ra, radiologists; Values in bold highlight a reached consensus within a specialty.
TABLE 3 | Check list of red flags sign or symptom suggestive of ILD.
Presence of basal velcro crackles on chest auscultation.
Dry cough and exertional dyspnea, not justified by an infectious
respiratory or cardiological pathology in progress.
A total of 76 clinicians (31 pulmonologists, 30
rheumatologists, and 15 radiologists) took part in
the second survey. All the questions are available as
Supplementary Material (Supplementary Tables).
Red Flags of ILD in Patients With ARD
Rheumatologists should pose particular attention to signs and
symptoms shown in Table 3 since they are useful red flags to
suspect an underlying ILD in patients with ARD. If any of these
is present, a high-resolution computed tomography (HRCT)
should be prescribed.
Red Flags of ARD in Patients With ILD
Pulmonologists should pose particular attention to signs and
symptoms shown in Table 4 since they are useful red flags to
suspect an underlying ARD in patients with ILD. If any of these
is present, patients should be referred to a rheumatologist.
Screening and Monitoring of ILD in
Patients With ARD
Following indications given from the expert panel through
the Delphi survey and the second questionnaire, pulmonary
symptoms in the ARD patient should be assessed at each visit
(item 4.1, Table 1). Considering that the ARD-intrinsic risk of
TABLE 4 | Check list of red flags sign or symptom suggestive of ARD.
Skin manifestations (cutaneous sclerosis, purpura of the lower
limbs, Gottron’s papules, cutaneous vasculitis, photosensitivity,
palmar erythema, “mechanic’s hands”).
Raynaud’s phenomenon.
Digital ulcers and telangiectasias, alone or in combination.
Positivity to anti-nuclear antibodies with significant titer (≥1/160).
Presence of muscle weakness associated with an increase in CPK.
Arthralgia, joint swelling or swelling of the hands, morning stiffness.
Dry eyes and dry mouth.
onset and developing of ILDs changes according to specific
ARDs (items 1, Table 1) (19), the timing and type of screening
and monitoring must be evaluated according to the specific
pathology, and the overall clinical condition of the patient.
ILD in Patients With RA
Clinically evident ILD is usually reported in 7–10% of patients
with RA (20, 21), and lifetime risk of RA-ILD of 7.7% has been
reported in a population-based cohort study conducted in the
USA (22). However, prevalence largely varied according to the
different studies and it is significantly higher when consecutive
patients are evaluated by HRCT, recording abnormalities
compatible with ILD in up to one-third of cases (23–25).
Although the few available data, generally based on
retrospective studies, male sex, older age at RA onset, and
ever-smokers are associated with RA-ILD in majority of
studies (26, 27), mainly for patients with a usual interstitial
pneumonia pattern.
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aDo not delay spirometry if DLCO is not available in a short time.
bDiscrepancy between FVC and DLCO deficiency may suggest the presence of
pulmonary hypertension.
cHRCT should be performed (1) in case of a worsening of clinical symptoms or lung
function tests or (2) in stable patients to exclude lung cancer and to monitor lung disease.
*Presence of basal Velcro crackles, dry cough, and exertional dyspnea, not justified by a
respiratory infection or cardiological pathology in progress.
§FVC and/or TLC and/or DLCO deficit ≥20%.
◦ Infection, cancer, heart failure, drug toxicity.
Despite contrasting results, anti-citrullinated peptide
antibodies (ACPA) have been also associated to ILD. In
particular, Correia reported a correlation between ACPA titer
and the risk to develop ILD (28). Finally, Doyle reported that a
combination of older age, male sex, ever-smoking, RF, and ACPA
was strongly associated with RA-ILD (29).
The Steering committee analyzed the answers from both the
Delphi and the second survey, discussed such answers, compared
them with available literature, integrated them with its opinion,
and drafted a practical checklist for screening and monitoring of
ILD in patients with RA, as shown in Table 5.
ILD in Patients With SSc
Interstitial lung disease is a common manifestation of SSc, with
approximately one-third of patients developing progressive ILD
(30). Fibrotic non-specific interstitial pneumonia is the most
common feature of parenchymal lung disease in patients with
SSc-associated ILD, followed by usual interstitial pneumonia.
Both the forms appear to have a similar survival in patients with
SSc (31, 32). Despite significant improvement in the overall 10-
year survival in SSc patients in the last few years, ILD represents
a significant cause of morbidity and mortality. Risk factors for
the development or progression of ILD among patients with
SSc include diffuse cutaneous SSc, male sex, African–American
race, older age at disease onset, shorter disease duration, and
the presence of anti-Scl-70/anti-topoisomerase I antibody (33–
36). However, none of these risk factors is absolute. Clinicians














































aRisk factors should be assessed at every examination. Risk factors include male gender,
diffuse skin disease, and presence of anti-Scl70 antibodies.
*Presence of basal velcro crackles, dry cough and exertional dyspnea, not justified by a
respiratory infection or cardiological pathology in progress.
◦ Infection, cancer, heart failure, drug toxicity.
∧Do not delay spirometry if DLCO is not available in a short time.
should remember that ILD may develop even in patients with
limited cutaneous SSc. In addition, SSc-ILD has a variable and
not predictable clinical course. Most patients experience a slow
decline in lung function, but others have a rapid progression
just after disease onset (37). Different studies showed that
the most important predictors of mortality in patients with
SSc-ILD are the short-term changes in pulmonary functional
parameters (38, 39) and extent of lung fibrosis on HRTC. Despite
physicians knowing the established relationship between SSc-ILD
and mortality and morbidity well, the lack of a consensus on ILD
screening, and monitoring of disease progression raise important
implications for a better therapeutic management of SSc-ILD
patients, mainly for new available treatment options.
The Steering committee analyzed the answers from both the
Delphi and the second survey, discussed such answers, compared
them with available literature, integrated them with its opinion,
and drafted a practical checklist for screening and monitoring of
ILD in patients with RA, as shown in Table 6.
ILD in Patients With Other ARD
The other ARD considered in our questions are systemic
lupus erythematosus, Sjögren’s syndrome, mixed CTD,
polymyositis/dermatomyositis, undifferentiated CTD. The risk
to develop an ILD varies between different diseases, but in some
the mortality related to interstitial lung involvement is very high
(i.e., in the antisynthetase syndrome, 28% developed progressive
respiratory failure and died) (40). The high heterogeneity
spectrum of these diseases either in the risk to develop an ILD
either in clinical manifestations and in progression of lung
involvement reduced the consensus of the statement that varies
from 5 to 75% in the timing of performing CT scan and from 4.5
to 70% in timing to a perform function test.
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Regarding identification and monitoring of ILD associated
with these ARDs, the respiratory signs and symptoms to be
valued are the same as the ones presented for RA and SSc.
Diffusing capacity of the lungs for carbon monoxide (DLCO)
should be performed annually, or every 3–6 months in case
of an already diagnosed ILD. In patients without an ILD
diagnosis, HRCT should be performed when clinically indicated
from symptoms, or, in patients at high risk for the clinical
characteristics of the disease, every 12–24 months. If ILD
has been already diagnosed, HRCT should be carried out at
least annually.
The Multidisciplinary Approach
All statements addressing how to increase sensitivity and
attention to the suspicion of ILD in the Italian setting
(Q5 and Q6, Table 1) reached consensus. Their approaches
include the creation of a network between different centers of
reference, webinar/seminar with MDT, monothematic courses,
regional periodic scientific tables with simulation of MDT on
paradigmatic cases or participation in multidisciplinary clinics,
sharing literature, and the creation of an informatic platform,
where level 1 centers can ask more specialized centers’ opinion.
Statements referring to key question number 6 addressed how
to implement multidisciplinary management of ARD patients
with suspicion of ILD. Statements that reached consensus
suggest the creation of shared clinics between rheumatologists
and pulmonologists, the organization of joint training courses
between rheumatologists, pulmonologists, and radiologists, the
creation of a preferential path of access to rheumatologists and
pulmonologists for patients with suspected ILD secondary to
ARD, and sharing of diagnostic classification criteria of both
ARD and ILD among the rheumatological and pneumological
community. The only statement (6.6, Table 2) that did not reach
consensus suggested the creation of “smart” digital platforms for
each MDT group. However, consensus for this statement was
reached among the radiologists, likely because of them being
more prone in working in a digital setting given their every-day
work always involves computers.
DISCUSSION
Interstitial lung disease is often associated with rheumatic
diseases. Its early diagnosis and management are not only
difficult, but also crucial, because it is associated with major
morbidity and mortality and can be the first cause of death
in ARDs (7–13). We, therefore, aimed to measure consensus
between specialists who can be involved in its management: this
is one of the very first studies to address consensus between
pulmonologists, rheumatologists, and radiologists. Consensus
was high, with 42 out of 50 statements that reached the 75%
threshold agreement. No statements reached the disagreement
threshold. With this work we also aimed at highlighting
the importance of a multidisciplinary approach that includes
rheumatologists, and at providing the drafted checklists (see
Tables 3–6) as a practical tool useful in the prompt recognition
and in follow-up of ARD-ILD.
The main strength of this study is the combinations of
techniques, such as NGT and Delphi Survey, which allow
clinicians firstly to share their own opinion rising from
their personal experience, and secondly to work toward an
integration of such opinions. This methodology highlights
the multidisciplinary approach of this work. The importance
of multidisciplinary approaches has been consolidated in the
clinical practice, and it is of utmost important to keep such an
approach for diagnosis, therapy and follow-up. The evaluation
of ILD by an MDT has been proposed as the gold standard
for its management (41) but, while up to 20% of ILD
cases can be referred to rheumatic conditions, only ∼37% of
MDT cases worldwide include a rheumatologist (42); this may
create a vicious circle, where rheumatologist referral is up to
pulmonologist, who may underestimate clinical manifestation
of an ARD. Therefore, if we also consider that ILD can be the
leading cause of death for some ARD, and the exclusion of
any systemic ARD in any freshly diagnosed ILD is mandatory
according to current guidelines, we believe that rheumatologists’
non-inclusion in MDTs is not justifiable; their view could
potentially complete the evaluation of a pulmonologist, who
may overlook important details (15). With regards to this study,
when comparing factors taken into account by pneumologists
and rheumatologists to decide on the monitoring of the exams,
it shows such factors are more lung-related for pneumologists,
and more disease-specific for rheumatologists. Clinicians should
be aware of this “bias” since it could lead them in taking a wider
perspective on the pathology in exam.
Despite the high reached consensus, when we take a more in-
depth look to data from the surveys, and consider discussions
of the meetings of the steering committee, some discrepancies
arose in terms of attitude and management methods of the
disease among Delphi panelists, the steering committee, and
among clinicians of different expertise. For example, statement
1.5 “The severity of skin involvement in the case of SSc correlates
with an increased risk of ILD” reached a level of agreement of
77.8% within rheumatologists, 44.4% between radiologists and
25.8% within pneumologists. While it may be that disagreement
occurred because of actual lack of general knowledge or evidence,
it could also be argued that agreement occurred for the same
reasons. However, we believe this is not the case, since members
of the expert panel were chosen for their clinical experience in
ARD associated-ILDs and proven activity in MDTs. We think
result heterogenicity from the Delphi survey can be explained in
several different ways: the presence of specialists with different
backgrounds and sensitivities, and with specific experience on
different rheumatic diseases; the heterogeneity of rheumatic
diseases themselves, which require approaches that cannot be
generalized tout-court; a lack of international guidelines (except,
partially, on idiopathic pulmonary fibrosis), which may have
led panelists in sharing what they can do to the best of the
means at their disposal in the everyday clinical setting; the
need to reconcile the evaluation of pulmonary involvement with
that of the other systemic manifestations of the disease; the
difficulties of working in an MDT. Despite discrepancies arising
from the variability of different points of view, we managed
to integrate such diverse opinions through several meetings
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in which statements were discussed, compared to available
literature, and our clinical view, and we went so far as to give
our opinion based on our experience in MDTs. Notwithstanding
differences between specialists, some statements reach a really
strong consensus, with one of those being number 2.8 stating that
“the high-resolution CT scan of the chest is the most sensitive
and specific radiological method to validate the presence of ILD
in a patient with ARD,” and reaching a level of agreement of
100%. This is coherent with HRCT driving therapeutic choices,
given the fact that is useful to identify subclinical outlines, and
differentiate ILA from subclinical forms of ARD-ILD (19).
Training clinicians and improving their sensitivity and
attention to the suspicion of ARD-ILD can be a valuable
solution when working with an MDT is not possible; this
happens quite often in the Italian scenario, where the triplet
pulmonologist, rheumatologist, and radiologist is not always
available, or present within the same structure. Q5 of the
Delphi survey addressed how to implement such training;
results therefore show which ways clinicians would feel effective
if they had to be instructed. The two most-agreed ways
are the creation of a network between different centers of
reference, which also favors the organization of national
collaborative studies between pulmonologists, radiologists, and
rheumatologists, and an opportunity increase for meeting and
updating with experts, through regional periodic scientific
tables with simulation of MDT on paradigmatic cases or
participation in multidisciplinary clinics. Other solutions include
webinars/seminars with MDT and monothematic courses at
regional and national level, the creation of an informatic
platform, where level 1 centers can ask more specialized
centers’ opinion, and sharing literature through scientific bulletin
to be distributed to level 1 centers. Improving untrained
physicians’ sensitivity is the first step toward implementation
of ARD-ILD multidisciplinary management. Q6 of the Delphi
survey addressed ways for such implementations; statement
consensus was reached for four out of five statements.
According to the Delphi panelists, the most effective way to
implement multidisciplinary management is the organization of
joint training courses between rheumatologists, pulmonologists,
and radiologists, followed by the creation of shared clinics
between rheumatologists and pulmonologists, the sharing
of diagnostic classification criteria of both ARD and ILD
among the rheumatological and pneumological community (e.g.,
the formulation of statements by scientific societies or the
organization of regular meetings for the discussion of cases),
and eventually the creation of a preferential path of access to
rheumatologists and pulmonologists for patients with suspected
ILD secondary to ARD. On top of this, it must be remembered
that being part of an MDT is an ongoing process. Even once
multidisciplinary management has been implemented, clinicians
need time to adapt to it: levels of agreement between different
specialists rise over time, improving diagnostic, and managing
performance (15, 43).
The solutions proposed in the statements from Q5 and Q6
could be effective, but they require a lot of time to be carried
on and applied. Moreover, not all clinical settings are suitable for
having an MDT. Because of this, and to provide all specialties
with tools that are shared and recommended by other specialists.
We propose some checklists to help recognition and follow
up of ARD-ILD; these checklists arise from the integration
of results from the Delphi survey, the second questionnaire,
and our experience of MDT. Given the irreversibility and high
morbidity and mortality rates of ILD (1, 44) a prompt diagnosis
is extremely important; the red-flag checklist of respiratory signs
and symptoms suggestive of ILD in ARD patients (Table 3)
can be a useful tool for rheumatologists for the recognition of
ILD. On the other hand, the red-flag checklist of systemic signs
and symptoms suggestive of ARD in ILD patients (Table 4) is
addressed to pulmonologist to help them recognize a rheumatic
condition underlying ILD. A fast recognition of the presence
of an ARD underlying ILD, and vice versa, can help guide
therapy and give better outcomes. Tables 5, 6 go more in-
depth tackling identification and monitoring of ILD in RA
and SSc, respectively. They explicit symptoms to be addressed
and examinations to be performed and give indication on the
timing depending on whether the rheumatic disease has just
been diagnosed, or patients are in the follow-up phase with
a diagnosed or undiagnosed ILD already. We believe these
short, easy-to-consult checklists can help untrained physicians
better address these pathologies in the wait of more robust,
international guidelines.
This study has four main limitations. Firstly, drafting items
and statement can often lead to them being redundant or
already addressed in literature Secondly, Delphi panelists
could not comment on the relevance or importance of
the drafted statements, as well as they could not give a
position of “non-opinion.” Thirdly, it is limited to the
Italian scenario; this may have yielded results that are
not in line with other countries’ reality, especially when
considering every-day clinical practice, which can differ
because of different regulations and resources. Finally,
albeit based on the experience of a high number of
clinicians, it is a consensus work and could not produce
empiric data.
CONCLUSIONS
This consensus work showed a high level of agreement, but also
shows some divergent opinions between different experts. This
underlines the importance of a multidisciplinary approach and
of a constant update in overcoming these differences and in
enhancing the diagnosis timing andmanagement of patients with
ILD-ARD. Given the high morbidity and mortality rates of ILD-
ARD, its early recognition is crucial. The expert-shared red-flag
checklist of respiratory signs and symptoms suggestive of ILD in
ARD patients (Table 3) can be a useful tool for rheumatologists
for the recognition of ILD, while the expert-shared red-flag
checklist of systemic signs and symptoms suggestive of ARD in
ILD patients can help the pulmonologist to recognize a rheumatic
condition underlying ILD (Table 4). Since RA and SSc are two
of the most common ARDs that can be associated with ILD,
we drafted related checklists on identification and monitoring
(Tables 5, 6), which can help tackle these conditions.
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